 [1m([0moverall-effect-renal failure-beta blocker[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug METOPROLOL TARTRATE: DO-NOT-KNOW[0m

[34mThe FDA label for METOPROLOL TARTRATE does not indicate that the drug increases or decreases the risk of renal failure. The adverse reactions table and other sections of the label do not mention renal[0m
[34mfailure as a known adverse effect or precaution. Therefore, based on the available FDA label data, it is not possible to determine if METOPROLOL TARTRATE has an effect on the risk of renal failure.[0m
[1;34m2[0m[34m. Drug LABETALOL: DO-NOT-KNOW[0m

[34mThe question was whether LABETALOL increases or decreases the risk of renal failure. After consulting with FDAHandler, the response indicated that the LABETALOL label does not specifically mention an [0m
[34mincrease or decrease in the risk of renal failure. However, it is noted that doses of labetalol that controlled hypertension did not affect renal function in patients with normal renal function. This [0m
[34minformation suggests that in the context of hypertension control, labetalol does not adversely affect renal function in patients with normal renal function. Nonetheless, the label advises monitoring [0m
[34mconditions such as impaired renal function in patients with concomitant illnesses. Therefore, based on the available FDA label data, it is not possible to definitively state whether LABETALOL [0m
[34mincreases or decreases the risk of renal failure.[0m
[1;34m3[0m[34m. Drug ATENOLOL: Atenolol has been reported to increase the risk of renal failure, but this occurs at a very low frequency of [0m[1;34m0.4[0m[34m% according to the drug label.[0m
[34m                ---------[0m
[34m                Does the beta blocker category of drugs increase the risk of[0m
[34m                renal failure, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-renal failure-beta blocker[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-renal failure-beta blocker[1m)[0m [31m Entity.AGENT [0m
*[1m([0moverall-effect-renal failure-beta blocker[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the beta blocker category of drugs increase the risk of renal failure, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"The FDA label for METOPROLOL TARTRATE does not indicate any known effect on the risk of renal failure."[0m[32m,[0m
[32m      [0m[32m"The FDA label for LABETALOL does not specifically mention an increase or decrease in the risk of renal failure, but suggests that it does not adversely affect renal function in patients with [0m
[32mnormal renal function when used for hypertension control."[0m[32m,[0m
[32m      [0m[32m"The drug label for ATENOLOL reports an increased risk of renal failure, but at a very low frequency of 0.4%."[0m[32m,[0m
[32m      [0m[32m"Given that two out of three drugs have no clear evidence of an effect on renal failure risk and one drug has a very low frequency of increased risk, it is not possible to conclude that the beta[0m
[32mblocker category as a whole has a clear effect on the risk of renal failure."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is no clear effect of the beta blocker category of drugs on the risk of renal failure."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-renal failure-beta blocker[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-renal failure-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-renal failure-beta blocker[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the beta blocker category of drugs increase the risk of renal failure, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"The FDA label for METOPROLOL TARTRATE does not indicate any known effect on the risk of renal failure."[0m[34m,[0m
[34m      [0m[34m"The FDA label for LABETALOL does not specifically mention an increase or decrease in the risk of renal failure, but suggests that it does not adversely affect renal function in patients with [0m
[34mnormal renal function when used for hypertension control."[0m[34m,[0m
[34m      [0m[34m"The drug label for ATENOLOL reports an increased risk of renal failure, but at a very low frequency of 0.4%."[0m[34m,[0m
[34m      [0m[34m"Given that two out of three drugs have no clear evidence of an effect on renal failure risk and one drug has a very low frequency of increased risk, it is not possible to conclude that the beta[0m
[34mblocker category as a whole has a clear effect on the risk of renal failure."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is no clear effect of the beta blocker category of drugs on the risk of renal failure."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the beta blocker category of drugs increase the risk of renal failure, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. The FDA label for METOPROLOL TARTRATE does not indicate any known effect on the risk of renal failure.[0m
[1;31m2[0m[31m. The FDA label for LABETALOL does not specifically mention an increase or decrease in the risk of renal failure, but suggests that it does not adversely affect renal function in patients with normal[0m
[31mrenal function when used for hypertension control.[0m
[1;31m3[0m[31m. The drug label for ATENOLOL reports an increased risk of renal failure, but at a very low frequency of [0m[1;31m0.4[0m[31m%.[0m
[1;31m4[0m[31m. Given that two out of three drugs have no clear evidence of an effect on renal failure risk and one drug has a very low frequency of increased risk, it is not possible to conclude that the beta [0m
[31mblocker category as a whole has a clear effect on the risk of renal failure.[0m
[31m        -----[0m
[31m        Final answer: There is no clear effect of the beta blocker category of drugs on the risk of renal failure.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is generally sound, but it could be improved by explicitly stating that the absence of information in the FDA data for the other drugs in the beta blocker [0m
[32mcategory is enough to conclude that there is no effect for those drugs on the risk of renal failure. Additionally, the reasoning could be more precise by stating that the evidence suggests no [0m
[32msignificant effect on the risk of renal failure for the beta blocker category as a whole, rather than stating there is no clear effect, which could imply a lack of data rather than data suggesting no [0m
[32msignificant effect."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-renal failure-beta blocker[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is generally sound, but it could be improved by explicitly stating that the absence of information in the FDA data for the other drugs in the beta blocker [0m
[34mcategory is enough to conclude that there is no effect for those drugs on the risk of renal failure. Additionally, the reasoning could be more precise by stating that the evidence suggests no [0m
[34msignificant effect on the risk of renal failure for the beta blocker category as a whole, rather than stating there is no clear effect, which could imply a lack of data rather than data suggesting no [0m
[34msignificant effect."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-renal failure-beta blocker[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is generally sound, but it could be improved by explicitly stating that the absence of information in the FDA data for the other drugs in the beta blocker [0m
[31mcategory is enough to conclude that there is no effect for those drugs on the risk of renal failure. Additionally, the reasoning could be more precise by stating that the evidence suggests no [0m
[31msignificant effect on the risk of renal failure for the beta blocker category as a whole, rather than stating there is no clear effect, which could imply a lack of data rather than data suggesting no [0m
[31msignificant effect.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-renal failure-beta blocker[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-renal failure-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-renal failure-beta blocker[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the beta blocker category of drugs increase the risk of renal failure, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"The FDA label for METOPROLOL TARTRATE does not indicate any known effect on the risk of renal failure, suggesting no significant effect."[0m[32m,[0m
[32m      [0m[32m"The FDA label for LABETALOL does not specifically mention an increase or decrease in the risk of renal failure, but indicates that it does not adversely affect renal function in patients with [0m
[32mnormal renal function when used for hypertension control, again suggesting no significant effect."[0m[32m,[0m
[32m      [0m[32m"The drug label for ATENOLOL reports an increased risk of renal failure, but at a very low frequency of 0.4%, which is not enough to establish a clear effect for the category as a whole."[0m[32m,[0m
[32m      [0m[32m"Considering the absence of information on an increased or decreased risk of renal failure for two of the drugs and the very low frequency of increased risk for the third, the evidence suggests [0m
[32mno significant effect on the risk of renal failure for the beta blocker category as a whole."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is no significant effect of the beta blocker category of drugs on the risk of renal failure."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-renal failure-beta blocker[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-renal failure-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-renal failure-beta blocker[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the beta blocker category of drugs increase the risk of renal failure, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"The FDA label for METOPROLOL TARTRATE does not indicate any known effect on the risk of renal failure, suggesting no significant effect."[0m[34m,[0m
[34m      [0m[34m"The FDA label for LABETALOL does not specifically mention an increase or decrease in the risk of renal failure, but indicates that it does not adversely affect renal function in patients with [0m
[34mnormal renal function when used for hypertension control, again suggesting no significant effect."[0m[34m,[0m
[34m      [0m[34m"The drug label for ATENOLOL reports an increased risk of renal failure, but at a very low frequency of 0.4%, which is not enough to establish a clear effect for the category as a whole."[0m[34m,[0m
[34m      [0m[34m"Considering the absence of information on an increased or decreased risk of renal failure for two of the drugs and the very low frequency of increased risk for the third, the evidence suggests [0m
[34mno significant effect on the risk of renal failure for the beta blocker category as a whole."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is no significant effect of the beta blocker category of drugs on the risk of renal failure."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the beta blocker category of drugs increase the risk of renal failure, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. The FDA label for METOPROLOL TARTRATE does not indicate any known effect on the risk of renal failure, suggesting no significant effect.[0m
[1;31m2[0m[31m. The FDA label for LABETALOL does not specifically mention an increase or decrease in the risk of renal failure, but indicates that it does not adversely affect renal function in patients with [0m
[31mnormal renal function when used for hypertension control, again suggesting no significant effect.[0m
[1;31m3[0m[31m. The drug label for ATENOLOL reports an increased risk of renal failure, but at a very low frequency of [0m[1;31m0.4[0m[31m%, which is not enough to establish a clear effect for the category as a whole.[0m
[1;31m4[0m[31m. Considering the absence of information on an increased or decreased risk of renal failure for two of the drugs and the very low frequency of increased risk for the third, the evidence suggests no [0m
[31msignificant effect on the risk of renal failure for the beta blocker category as a whole.[0m
[31m        -----[0m
[31m        Final answer: There is no significant effect of the beta blocker category of drugs on the risk of renal failure.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The revised reasoning is more precise and accurately reflects the evidence provided. It correctly states that the absence of information for two drugs and the very low frequency of [0m
[32mincreased risk for the third drug suggest no significant effect on the risk of renal failure for the beta blocker category as a whole. The reasoning now clearly distinguishes between a lack of data [0m
[32mand data suggesting no significant effect, which is consistent with the evidence."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-renal failure-beta blocker[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The revised reasoning is more precise and accurately reflects the evidence provided. It correctly states that the absence of information for two drugs and the very low frequency of [0m
[34mincreased risk for the third drug suggest no significant effect on the risk of renal failure for the beta blocker category as a whole. The reasoning now clearly distinguishes between a lack of data [0m
[34mand data suggesting no significant effect, which is consistent with the evidence."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-renal failure-beta blocker[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The revised reasoning is more precise and accurately reflects the evidence provided. It correctly states that the absence of information for two drugs and the very low frequency of [0m
[31mincreased risk for the third drug suggest no significant effect on the risk of renal failure for the beta blocker category as a whole. The reasoning now clearly distinguishes between a lack of data [0m
[31mand data suggesting no significant effect, which is consistent with the evidence.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-renal failure-beta blocker[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-renal failure-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-renal failure-beta blocker[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"no-effect"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.8[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0.004[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"rare"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"weak"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"The FDA label for METOPROLOL TARTRATE and LABETALOL do not indicate any known effect on the risk of renal failure, suggesting no significant effect for these drugs. ATENOLOL has [0m
[32ma reported increase in the risk of renal failure, but at a very low frequency of 0.4%. Therefore, the evidence suggests no significant effect on the risk of renal failure for the beta blocker category[0m
[32mas a whole. The confidence is not absolute due to the limited data available and the very low frequency of increased risk reported for ATENOLOL."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-renal failure-beta blocker[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
